242 related articles for article (PubMed ID: 20376628)
1. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Gawrońska-Szklarz B; Siuda A; Kurzawski M; Bielicki D; Marlicz W; Droździk M
Eur J Clin Pharmacol; 2010 Jul; 66(7):681-7. PubMed ID: 20376628
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.
Kurzawski M; Gawrońska-Szklarz B; Wrześniewska J; Siuda A; Starzyńska T; Droździk M
Eur J Clin Pharmacol; 2006 Oct; 62(10):877-80. PubMed ID: 16912869
[TBL] [Abstract][Full Text] [Related]
3. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
[TBL] [Abstract][Full Text] [Related]
6. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Zhang L; Mei Q; Li QS; Hu YM; Xu JM
J Clin Pharm Ther; 2010 Dec; 35(6):713-22. PubMed ID: 21054464
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K
Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Bochenek WJ; Peters S; Fraga PD; Wang W; Mack ME; Osato MS; El-Zimaity HM; Davis KD; Graham DY;
Helicobacter; 2003 Dec; 8(6):626-42. PubMed ID: 14632678
[TBL] [Abstract][Full Text] [Related]
9. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
11. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β].
Bakulina NV; Maev IV; Savilova IV; Bakulin IG; Il'chishina TA; Zagorodnikova KA; Murzina AA; Andreev DN
Ter Arkh; 2019 Aug; 91(8):34-40. PubMed ID: 32598752
[TBL] [Abstract][Full Text] [Related]
13. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
15. Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Lay CS; Lin CJ
J Chin Med Assoc; 2010 Apr; 73(4):188-93. PubMed ID: 20457439
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
[TBL] [Abstract][Full Text] [Related]
17. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study.
Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V
Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
19. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
